Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors
Nathan A. Brooks(Eli Lilly (United States)), Laurie A. LeBrun(Eli Lilly (United States)), Candace Langan, Wei Zheng(Liaoning Cancer Hospital & Institute), Janice Y. Lee(Foghorn Therapeutics (United States)), Hai Hu(China University of Petroleum, East China), Bonita D. Jones, Rowena Almonte‐Baldonado(Eli Lilly (United States)), Shuang Chen(Institute of Plant Protection), Xiaodong Huang(Eli Lilly (United States)), Kevin Wilson(Blueprint Medicines (United States)), Renan Escalante Chong(Eli Lilly (United States)), Anke Klippel(Eli Lilly (United States)), Robert S. Flack, Bryan Perria
Cited by 0
Related Papers
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225